[EN] PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS<br/>[FR] PROMÉDICAMENT BIPYRIDYLAMINOPYRIDINES EN TANT QU'INHIBITEURS DE SYK
申请人:MERCK SHARP & DOHME
公开号:WO2014074421A1
公开(公告)日:2014-05-15
The present invention provides compounds of Formula (I), which are prodrugs of trans-4-[(1R)-(6-[4-(difluoromethyl)pyridin-2-yl]amino}-4-methyl-2,3'-bipyridin-6'-yl)-1-hydroxyethyl]cyclohexanecarboxylic acid, a potent inhibitor of Syk. The compounds are useful in the treatment and prevention of diseases mediated by the enzyme, such as asthma, COPD, rheumatoid arthritis and cancer.
From Enantiopure Hydroxyaldehydes to Complex Heterocyclic Scaffolds: Development of Domino Petasis/Diels-Alder and Cross-Metathesis/Michael Addition Reactions
作者:Alexandre Cannillo、Stéphanie Norsikian、Marie-Elise Tran Huu Dau、Pascal Retailleau、Bogdan I. Iorga、Jean-Marie Beau
DOI:10.1002/chem.201402965
日期:2014.9.15
One‐step assembly of hexahydroisoindole scaffolds by a sequence that combines the Petasis (borono‐Mannich) and Diels–Alder reactions is described. The unique selectivity observed experimentally was confirmed by quantum calculations. The current method is applicable to a broad range of substrates, including free sugars, and holds significant potential to efficiently and stereoselectively build new heterocyclic
PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS
申请人:ICOS CORPORATION
公开号:EP1242400A1
公开(公告)日:2002-09-25
PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:EP2916837A1
公开(公告)日:2015-09-16
[EN] PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE PYRROLIDINE CONVENANT COMME INHIBITEURS DE LA PHPSPHODIESTERASE A SPECIFICITE AMP CYCLIQUE
申请人:ICOS CORP
公开号:WO2001047905A1
公开(公告)日:2001-07-05
Novel pyrrolidine compounds having the structural formula (II) that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.